Keratoacanthoma - ケラトアカントーマ
☆ AI Dermatology — Free Service
ドイツの2022年Stiftung Warentestの結果では、ModelDermに対する消費者満足度は有料の遠隔医療相談よりもわずかに低いだけでした。
ドイツの2022年Stiftung Warentestの結果では、ModelDermに対する消費者満足度は有料の遠隔医療相談よりもわずかに低いだけでした。
通常、ケラトアカントーマ (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) は、急速に増殖し、自然に退縮することがあると知られる頻繁に発生する皮膚腫瘍です。主に、日光によるダメージを受けた経験のある高齢の色白男性に見られます。治療法としては、切除やMohs顕微鏡手術による外科的除去が一般的ですが、他にもさまざまな選択肢があります。
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) は、皮膚の特定の腺にできる低悪性度の腫瘍で、顕微鏡下では squamous cell carcinoma (SCC) に似ています。KA を侵襲性 SCC の一種として分類すべきかどうかは、現在も議論が続いています。
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) は、特に高齢者に多く見られる、癌の中で2番目に多いタイプです。cSCC の治療には通常手術が選択されますが、手術が受けられない、あるいは手術を受けないことを選択した患者に対しては、病変内治療などの代替手段が検討されます。従来は methotrexate や 5‑fluorouracil を用いた病変内治療が行われてきましたが、病変内免疫療法や腫瘍溶解性ウイルス療法といった新しいアプローチに関する研究が進んでいます。ここでは、古典的な方法から最先端の戦略まで、cSCC のさまざまな病変内治療を紹介します。
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
顕微鏡で観察すると、 ケラトアカントーマ (keratoacanthoma) は扁平上皮癌と非常によく似ています。一部の病理学者は ケラトアカントーマ (keratoacanthoma) を悪性腫瘍ではなく、別個の存在として分類していますが、臨床的および組織学的に見て、 ケラトアカントーマ (keratoacanthoma) の約6%は浸潤性・侵襲性の扁平上皮癌へ進行します。
○ 診断と治療
#Dermoscopy
#Skin biopsy